AGRN and familial pancreatic carcinoma: These results suggest that AGRN could be a therapeutic target in pancreatic cancer and, simultaneously, AGRN-positive CSCs extracellular vesicles can serve as prognostic biomarkers associated with increased risk for disease progression [92].